Analyst Ratings For Esperion Therapeutics (NASDAQ:ESPR)
Today, Needham & Company LLC raised its price target on Esperion Therapeutics (NASDAQ:ESPR) to $94.00 per share.
Some recent analyst ratings include
- 1/22/2018-Citigroup was Downgraded by analysts at Citigroup from a “Buy ” rating to a ” Neutral” rating. They now have a $96.00 price target on the stock, up previously from $77.00 .
- 1/17/2018-Credit Suisse Group initiated coverage with a Outperform rating.
- 1/5/2018-Bank of America Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 11/10/2017-Northland Securities Reiterated Rating of Buy.
Recent Insider Trading Activity For Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics (NASDAQ:ESPR) has insider ownership of 32.50% and institutional ownership of 87.67%.
- On 1/25/2018 Nicole Vitullo, Director, sold 11,674 with an average share price of $71.79 per share and the total transaction amounting to $838,076.46.
- On 12/6/2017 Nicole Vitullo, Director, sold 9,326 with an average share price of $53.85 per share and the total transaction amounting to $502,205.10.
- On 3/22/2017 Dov A Md Goldstein, Director, sold 800,000 with an average share price of $41.66 per share and the total transaction amounting to $33,328,000.00.
- On 3/21/2017 Gilbert S Omenn, Director, bought 1,000 with an average share price of $42.26 per share and the total transaction amounting to $42,260.00.
- On 11/1/2016 Narendra D Lalwani, COO, bought 5,000 with an average share price of $9.93 per share and the total transaction amounting to $49,650.00.
- On 7/6/2016 Mark E Mcgovern, Director, bought 5,000 with an average share price of $10.00 per share and the total transaction amounting to $50,000.00.
- On 5/4/2016 Timothy M Mayleben, CEO, bought 7,000 with an average share price of $14.85 per share and the total transaction amounting to $103,950.00.
Recent Trading Activity for Esperion Therapeutics (NASDAQ:ESPR)
Shares of Esperion Therapeutics closed the previous trading session at 77.90 up +2.11 2.78% with shares trading hands.